Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $165.00 price objective on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on the stock. UBS Group upped their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their target price for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. BMO Capital Markets upped their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Piper Sandler cut their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, Royal Bank of Canada upped their target price on shares of Sarepta Therapeutics from $181.00 to $182.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $182.95.

Sarepta Therapeutics Stock Up 1.1 %

Shares of NASDAQ SRPT opened at $129.88 on Monday. The firm’s 50-day simple moving average is $128.87 and its 200 day simple moving average is $132.42. The company has a market cap of $12.28 billion, a price-to-earnings ratio of 1,180.73 and a beta of 0.82. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) EPS. On average, research analysts expect that Sarepta Therapeutics will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in SRPT. GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares in the last quarter. Mather Group LLC. bought a new position in shares of Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Sarepta Therapeutics by 100.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock worth $647,000 after acquiring an additional 2,504 shares in the last quarter. Hudson Capital Management LLC bought a new position in shares of Sarepta Therapeutics during the 1st quarter worth approximately $220,000. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Sarepta Therapeutics by 8.7% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock valued at $679,000 after buying an additional 418 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.